Positron Emission Tomography Scanners Market to Reach USD 1.03 Billion by 2032

Key Highlights

Market valued at USD 688.47 million in 2025 and projected to reach USD 1.03 billion by 2032.
CAGR estimated at 5.9% during 2026–2032.
Rising global cancer incidence remains the largest demand catalyst.
Hybrid PET/CT and PET/MRI systems are improving diagnostic precision.
Hospitals remain the largest end-user segment due to high patient volumes and advanced infrastructure.
North America maintains market leadership through technology adoption and reimbursement support.
AI-enabled imaging platforms and total-body PET systems are reshaping workflow efficiency.
Short radiotracer half-life and reimbursement pressures remain major commercial constraints.

Why This Matters Now

Healthcare providers are shifting toward precision diagnostics that detect disease earlier while improving treatment planning. PET scanners have become central to oncology, neurology, and cardiology because they provide functional imaging beyond conventional anatomical scans. AI integration, total-body PET platforms, and innovative financing models are reducing operational barriers, expanding access, and increasing scanner utilization. These developments are reshaping procurement strategies across hospitals, research institutions, and diagnostic centers.

Market Overview

The Positron Emission Tomography (PET) Scanners Market Size covers imaging systems that visualize metabolic and functional activity using radioactive tracers. PET technology plays an essential role in diagnosing cancer, neurological disorders, and cardiovascular diseases while supporting therapy monitoring and clinical research.

Market demand is being driven primarily by the growing prevalence of chronic diseases, particularly cancer. Increasing adoption of molecular imaging, expansion of nuclear medicine procedures, and greater emphasis on early diagnosis continue to strengthen equipment demand worldwide.

The integration of PET with computed tomography (PET/CT) and magnetic resonance imaging (PET/MRI) has significantly improved diagnostic accuracy. Healthcare providers increasingly prefer hybrid imaging platforms because they combine anatomical and metabolic information within a single examination, enabling faster and more informed clinical decisions.

However, supply-side limitations remain. Radiopharmaceuticals such as Fluorine-18 FDG have a short operational half-life, creating logistical challenges for production, transportation, and clinical scheduling. Continued reimbursement pressure also limits purchasing decisions for some healthcare providers

Key Trends Driving Growth

AI and Total-Body PET Innovation

Artificial intelligence is improving image reconstruction, lesion detection, and workflow automation. Total-body PET scanners deliver substantially higher sensitivity while reducing scan time and radiation exposure, increasing patient throughput and operational efficiency.

Expansion of Hybrid Imaging

PET/CT remains the preferred clinical platform, while PET/MRI adoption is increasing in neurological and research applications. Hybrid systems provide comprehensive diagnostic information that supports precision medicine.

Healthcare Financing Models Expand Access

Equipment-as-a-Service (EaaS) financing is emerging as an alternative to traditional capital expenditure. This approach enables hospitals and diagnostic centers to deploy advanced PET technology without significant upfront investment.

Growing Clinical Research Activity

PET imaging is increasingly used in pharmaceutical development, biomarker validation, and neurodegenerative disease research. This broadens market demand beyond routine clinical diagnostics.

Aging Population Increases Imaging Demand

Growing elderly populations worldwide are contributing to higher incidence of cancer, cardiovascular disease, Alzheimer’s disease, and Parkinson’s disease, expanding the need for advanced molecular imaging.

Explore detailed analysis, insights, and growth opportunities

Segment Insights

Dominant Segment: Hospitals

Hospitals account for the largest share of the global PET scanners market and are expected to maintain leadership throughout the forecast period.

Large hospitals manage high patient volumes across oncology, cardiology, and neurology departments, creating sustained demand for advanced imaging systems. Their financial capacity also supports investment in premium PET technologies, integrated diagnostic platforms, and specialized imaging professionals.

Hospitals increasingly utilize PET scanners for treatment planning, therapy monitoring, and clinical trials, maximizing equipment utilization while improving patient outcomes. This reinforces hospitals as the primary revenue generator for manufacturers.

Business impact: Manufacturers continue prioritizing hospital procurement contracts because they generate recurring service revenue, software upgrades, and long-term maintenance agreements.

Fastest-Growing Segment: Oncology Applications

Cancer diagnosis remains the fastest-expanding application area for PET imaging.

PET imaging enables earlier tumor detection, more accurate disease staging, treatment response assessment, and recurrence monitoring. Rising global cancer incidence continues to increase demand for high-resolution molecular imaging.

Business impact: Vendors are accelerating development of oncology-specific imaging software, AI-assisted diagnostics, and higher-sensitivity PET platforms to strengthen competitive differentiation.

Additional Key Sub-Segments

Full Ring PET Scanners

Full ring systems continue to dominate premium installations because they deliver superior image quality, higher sensitivity, and improved diagnostic confidence for complex clinical cases.

Diagnostic Imaging Centers

Independent imaging centers continue expanding PET adoption as outpatient diagnostic demand increases. However, capital investment limitations keep overall market share below hospitals.

Neurology and Cardiology

Neurology applications are expanding through Alzheimer’s and Parkinson’s disease research, while cardiology continues adopting PET for myocardial viability assessment and perfusion imaging.

Regional Growth Story

North America

North America remains the largest regional market due to advanced healthcare infrastructure, favorable reimbursement policies, strong research investment, and widespread adoption of hybrid imaging technologies. The United States continues driving equipment replacement cycles and premium technology deployment.

Europe

Europe benefits from established nuclear medicine programs and growing investments in molecular imaging infrastructure. Research collaborations and clinical innovation continue supporting adoption across major healthcare systems.

Asia-Pacific

Asia-Pacific represents the strongest long-term investment opportunity. Expanding healthcare infrastructure, growing cancer incidence, increasing healthcare spending, and government modernization initiatives are accelerating adoption across China, India, Japan, and Southeast Asia.

Middle East, Africa, and South America

These regions continue experiencing gradual market expansion as governments invest in advanced diagnostic capabilities. Alternative financing models and public-private partnerships are improving access to PET imaging technology where capital constraints previously limited deployment.

Competitive Landscape

Competition remains concentrated among established global imaging manufacturers with expertise across diagnostic imaging portfolios.

GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Canon Medical Systems Corporation, and United Imaging Healthcare continue competing through hybrid imaging innovation, AI integration, and premium system performance. Their comprehensive product portfolios and global service networks create significant competitive advantages.

Regional manufacturers including Neusoft Medical Systems, Shenzhen Anke High-Tech, and Mediso Ltd. are strengthening their positions by expanding localized manufacturing, offering competitive pricing, and addressing emerging market demand.

Recent collaborations demonstrate that competitive differentiation increasingly depends on imaging software, AI capabilities, financing flexibility, and research partnerships rather than hardware specifications alone. Vendors investing in total-body PET technology and specialized neurological imaging are positioning themselves for future premium market opportunities.

Recent Developments

January 2025: XingImaging opened a research facility in Connecticut featuring United Imaging’s NeuroExplorer brain PET scanner for advanced neurodegenerative disease research.
January 2025: EASE commissioned South Africa’s first pay-per-use hybrid PET-CT scanner, expanding diagnostic access through an Equipment-as-a-Service model.
June 2025: S.L. Raheja Hospital introduced an AI-enabled digital PET-CT scanner alongside a 3 Tesla MRI system to improve imaging speed and diagnostic precision.
June 2025: The National PET Imaging Platform expanded into Scotland with a total-body PET scanner capable of significantly faster imaging and higher patient throughput.
September 2025: Algernon Pharmaceuticals secured financing to deploy four FDA-cleared Oncovision CareMiBrain brain-specific PET scanners, reducing patient radiation exposure.
March 2021: Cerveau Technologies partnered with Alector to commercialize an investigational PET imaging agent for monitoring neurofibrillary tangles.
February 2021: Siemens Healthineers installed its Biograph Vision PET/CT system at the Hospital of the University of Pennsylvania, marking the first U.S. deployment.

Future Outlook

Manufacturers that combine AI-enabled imaging, total-body PET technology, and flexible deployment models while expanding oncology and neurology applications will capture the strongest competitive advantage as precision diagnostics become central to modern healthcare.

Analyst Perspective Komal Patil

The Positron Emission Tomography (PET) Scanners Market is transitioning from a conventional diagnostic imaging segment to a strategic pillar of precision medicine. While oncology continues to generate the majority of equipment demand, the next phase of market expansion will be driven by neurological imaging, cardiovascular diagnostics, and clinical research requiring highly sensitive molecular imaging systems. As healthcare providers prioritize earlier disease detection and personalized treatment pathways, PET technology is becoming an increasingly critical investment rather than an optional imaging modality.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

Contact Us :

2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
+91 9607365656
sales@maximizemarketresearch.com